Agilent pd-l1 ihc 28-8 pharmdx receives ce-ivd mark as a companion diagnostic test in advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced it has received ce-ivd mark approval for the pd-l1 ihc 28-8 pharmdx to guide options for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. gastric (stomach) cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths
A Ratings Summary
A Quant Ranking